Allogeneic HSCT in Pediatric Solid Tumors and Lymphomas
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Relapsed and/or Chemotherapy Resistant Pediatric Solid Tumors and Lymphomas using Nonmyeloablative Reduced Intensity Conditioning
Protocol ID
Protocol Description
Blood and bone marrow transplantation (BMT) is used as a treatment for many forms of cancer. It involves giving high doses of treatment with chemotherapy to try and kill the cancer cells before bone marrow or stem cells are given to the patient. Because of damage to the bone marrow, the marrow needs to be replaced by stem cells from a donor or from the patient. This is the standard care for transplantation in patients with cancer. A risk of this treatment is that it can cause injury to vital organs such as the lungs, liver and kidneys, from the chemotherapy and/or radiation.
The purpose of this clinical research study is to evaluate the effectiveness of low intensity chemotherapy followed by an infusion of blood forming stem cells.
Eligibility Criteria
Patients with a diagnosis of a solid tumor or lymphoma that have developed progressive disease or are in partial remission in spite of standard doses of chemotherapy
Primary Investigator(s)
- Indira Sahdev, MD